Asensus Surgical

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Asensus Surgical reports Q1 loss but eyes stability through acquisition

Asensus Surgical's Q1 2024 performance showed a significant net loss, but the potential acquisition by KARL STORZ offers financial stability. The company aims to sustain operations into Q3 2024 and beyond with available cash and additional financing. Ongoing initiatives focus on advancing surgical systems and expanding global programs.

Asensus Surgical reports Q2 losses, merger vote adjourned

Asensus Surgical faces financial struggles with a significant net loss and liquidity concerns.
The proposed merger with Karl Storz offers a potential strategic advantage but hinges on stockholder approval.
Addressing operational inefficiencies and investor engagement are critical for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the first quarter 2021. Recent Highlights Signed two lease agreements with hospitals to install Senhance® Surgical Systems A hospital completed the first buyout of a previously leased Senhance Surgical S

Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2021

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced LAKUMED hospitals has entered into an agreement to lease and utilize a Senhance® Surgical System. The system will be utilized at the Landshut-Achdorf hospital which is located in the Landshut region, just outside of Munich, Germany. “We are very p

Asensus Surgical Announces LAKUMED Hospitals in Germany to Initiate Senhance Program

Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.

What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?

Boston Scientific

Intuitive Surgical

Johnson & Johnson

Stryker

Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).

Innovation Drives Robotic-Assisted Surgery: 5 Stocks to Watch

ASXC stock is an interesting play in the digital surgery space, especially with surgery numbers expected to pick up in the coming months. The post Asensus Surgical Is a Great Investment, but Not Much of a Retail Trade appeared first on InvestorPlace.

Asensus Surgical Is a Great Investment, but Not Much of a Retail Trade

Asensus Surgical (ASXC) closed at $2.10 in the latest trading session, marking a -1.87% move from the prior day.

Asensus Surgical (ASXC) Dips More Than Broader Markets: What You Should Know

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2021 first quarter financial and operating results after the market closes on Tuesday, May 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 11, 2021

GT Biopharma Inc

Zomedica

These biotech penny stocks have begun turning heads in April 2021 The post 3 Penny Stocks To Watch As Biotech Surges In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch As Biotech Surges In April 2021

Iterum Therapeutics Plc

Onconova Therapeutics

Biotech penny stocks continue to see momentum; should you add these 3 to your watchlist? The post Top Biotech Penny Stocks to Buy?

Top Biotech Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021

Today, investors in ASXC stock are seeing some very nice gains as optimism grows in the surgical sector coming out of this pandemic. The post ASXC Stock: Why Penny Stocks Play Asensus Surgical Is Soaring Today appeared first on InvestorPlace.

ASXC Stock: Why Penny Stocks Play Asensus Surgical Is Soaring Today

Castor Maritime Inc

Genius Brands

Hall of Fame Resort & Entertainment

Ideanomics Inc

Cenntro Electric Group

Ocugen, Inc.

SNDL Inc.

Once flying high on their status as Reddit stocks, these nine penny stocks are falling back towards prior price levels. The post 9 Reddit Penny Stocks That Are Running Out of Gas appeared first on InvestorPlace.

9 Reddit Penny Stocks That Are Running Out of Gas

Investors need to pay close attention to Asensus (ASXC) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Asensus (ASXC) Stock?

ASXC stock rode the Reddit rally up. Now the business has to deliver — but there's simply not enough evidence to bet on that happening.

Asensus Surgical Can't Support This Valuation and Won't Anytime Soon

Investors may be well-served by having a look at this company's financials before buying TRXC stock. The post Asensus Surgical's Name Has Changed, But Investors' Valuation Concerns Haven't appeared first on InvestorPlace.

Asensus Surgical's Name Has Changed, But Investors' Valuation Concerns Haven't

ASXC stock is extremely overvalued. And that means that investors may be waiting a long time for the stock to meet its lofty expectations.

Investing in Asensus Surgical Requires the Patience of a Surgeon

With the jury still out whether its Sehance digital-surgery system is finally ready for primetime, there's no use buying into ASXC stock at today's inflated price. The post Despite Name Change, Asensus Stock Is Still One to Avoid appeared first on InvestorPlace.

Despite Name Change, Asensus Stock Is Still One to Avoid

Before you consider investing in ASXC stock, you'll definitely want to be aware of the important changes going on in the stock and company. The post In a Time of Transition, Asensus Surgical Stock Remains a Worthy Investment appeared first on InvestorPlace.

In a Time of Transition, Asensus Surgical Stock Remains a Worthy Investment

Asensus Surgical Inc (ASXC) CEO Anthony Fernando on Q4 2020 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the fourth quarter and full-year 2020. Recent Highlights Senhance Surgical System received expanded 510(k) clearance for general surgery indication Asensus Surgical received CE Mark for Intelligent Surgi

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2020

AIM ImmunoTech Inc

Celsion

iBio

Jaguar Health

Ovid Therapeutics

Rigel Pharmaceuticals

VBI Vaccines

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

8 Biotech Penny Stocks for Investors to Watch

TransEnterix is now Asensus Surgical. However, this is unlikely to improve sales for Asensus' floundering line of products.

A Name Change Won't Fix the Disaster That Is Asensus Surgical

TransEnterix

Whether you're looking to invest in TRXC stock or its successor, Asensus Surgical, you'll need something to handle the volatility.   The post TransEnterix or Asensus Surgical?

TransEnterix or Asensus Surgical? Let's Call the Whole Thing Off

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the formal completion of its previously announced name and ticker symbol change.

Asensus Surgical Announces Finalization of Name and Ticker Symbol Change

News for Asensus Surgical Stock (ASXC)